Mineralys Therapeutics, Inc. (MLYS): Shareholders' Equity
$646.69M
As of 2025-12-31
$550.92M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $646.69M | +238.1% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $191.26M | -20.7% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $241.15M | n/m | 2025-02-12, Balance as of period end |
| 2022-12-31 | -$52.27M | n/a | 2024-03-21, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | 2025-12-31 | $646.69M | +238.1% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $614.71M | -9.0% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $459.28M | -5.5% |
| Immunome Inc. (IMNM) | 2025-12-31 | $634.34M | +250.1% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $518.36M | +147.4% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $538.75M | +2.2% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $88.30M | +54.9% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $581.76M | -22.9% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $639.06M | -27.4% |
Compare MLYS, PTGX, AMRN, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗